Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

Valuation Down 42.3% Over Two Days

 
• By Mandy Jackson
  
Sarepta faced a one-two punch on 6 May when it reported Q1 earnings (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Scrip